Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.
Guardado en:
Autores principales: | Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen, Hanbing An, Yuguang Ban, Hanchen Huang, Lily Wang, Jamaal L. James, Justin M. Balko, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Bing Zhang, Jennifer A. Pietenpol, X. Steven Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0cee2f33898a4f86bcaa6cb1a2d39df1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Multi-omics subtyping pipeline for chronic obstructive pulmonary disease.
por: Lucas A Gillenwater, et al.
Publicado: (2021) -
Evaluation and comparison of multi-omics data integration methods for cancer subtyping.
por: Ran Duan, et al.
Publicado: (2021) -
Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Gábor Cserni, et al.
Publicado: (2021) -
Integrative multi-omic analysis identifies new drivers and pathways in molecularly distinct subtypes of ALS
por: Giovanna Morello, et al.
Publicado: (2019) -
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
por: Sia Viborg Lindskrog, et al.
Publicado: (2021)